BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Dow
Johnson and Johnson
Novartis
Covington
McKesson
Accenture
Harvard Business School
Queensland Health
Fuji

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,433,624

« Back to Dashboard

Which drugs does patent 9,433,624 protect, and when does it expire?

Patent 9,433,624 protects KUVAN and is included in two NDAs.

This patent has sixteen patent family members in seventeen countries.
Summary for Patent: 9,433,624
Title:Methods and compositions for the treatment of metabolic disorders
Abstract: The present invention is directed to a novel methods and compositions for the therapeutic intervention in hyperphenylalaninemia. More specifically, the specification describes methods and compositions for treating various types of phenylketonurias using compositions comprising BH4. Combination therapies of BH4 and other therapeutic regimens are contemplated.
Inventor(s): Oppenheimer; Daniel I. (Castro Valley, CA), Kakkis; Emil D. (Novato, CA), Price; Fredric D. (Bedford, NY), Dorenbaum; Alejandro (Mill Valley, CA), Moser; Rudolf (Schaffhausen, CH), Groehn; Viola (Dachsen, CH), Egger; Thomas (Kempthal, CH), Blatter; Fritz (Reinach, CH)
Assignee: BIOMARIN PHARMACEUTICAL INC. (Novato, CA)
Application Number:13/297,644
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 9,433,624

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Biomarin Pharm KUVAN sapropterin dihydrochloride POWDER;ORAL 205065-001 Dec 19, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA ➤ Subscribe
Biomarin Pharm KUVAN sapropterin dihydrochloride POWDER;ORAL 205065-002 Oct 27, 2015 RX Yes No ➤ Subscribe ➤ Subscribe METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA ➤ Subscribe
Biomarin Pharm KUVAN sapropterin dihydrochloride TABLET;ORAL 022181-001 Dec 13, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,433,624

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,566,714 Methods and compositions for the treatment of metabolic disorders ➤ Subscribe
8,067,416 Methods and compositions for the treatment of metabolic disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,433,624

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2004291149 ➤ Subscribe
Brazil PI0416566 ➤ Subscribe
Canada 2545584 ➤ Subscribe
China 1905863 ➤ Subscribe
Cyprus 1118171 ➤ Subscribe
Denmark 1708690 ➤ Subscribe
European Patent Office 1708690 ➤ Subscribe
European Patent Office 3138566 ➤ Subscribe
Spain 2596827 ➤ Subscribe
Hong Kong 1094875 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Farmers Insurance
Johnson and Johnson
Cipla
Moodys
Fish and Richardson
AstraZeneca
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot